Carcinoma of unknown primary site: The poster child for personalized medicine?

JAMA Oncology

Volumn 1, Issue 1, 2015, Pages 19-21

  Varadhachary, Gauri ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ADENOCARCINOMA; CANCER OF UNKNOWN PRIMARY SITE; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; MALE; MOLECULARLY TARGETED THERAPY; PERSONALIZED MEDICINE; PROCEDURES;

ADENOCARCINOMA; BIOMARKERS, TUMOR; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASMS, UNKNOWN PRIMARY; PRECISION MEDICINE;

EID: 84982952321     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2014.277     Document Type: Editorial

References (5)

1. Ross JS, Wang K, Gay L, et al. Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies [published online February 12, 2015]. JAMA Oncol. 10.1001/jamaoncol.2014.216.
2. National Comprehensive Cancer Network. Occult Primary (Cancer of Unknown Primary) version 1. 2015. http://www.nccn.org/professionals/physician-gls/pdf/occult.pdf. Accessed December 2014.
3. Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005;11(10):3766-3772.
4. Varadhachary GR, Karanth S, Qiao W, et al. Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset. Int J Clin Oncol. 2014;19(3):479-484.
5. NCI-MPACT: Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT01827384?term=MPACT&rank=3. Accessed December 2014.